Thursday - March 12, 2026

Category Archives: Pharmaceuticals & Biotech

Projecting the Global Nanomedicine Market Size to Expand at a 10.47% CAGR Through 2034, DelveInsight Analysis

Nanomedicine Market Insights, Competitive Landscape, and Market Forecast – 2034” report provides the current and forecast market outlook, forthcoming device innovation, challenges, market drivers and barriers.   As per DelveInsight’s assessment, The nanomedicines market is chiefly fueled by the rising … Continue reading →

Chronic Myeloid Leukemia Clinical Trial Pipeline Appears Robust With 20+ Key Pharma Companies Actively Working in the Domain | DelveInsight | Kartos Therapeutics, AOP Orphan Pharmaceuticals

Chronic Myeloid Leukaemia – Pipeline Insight, 2026 DelveInsight’s latest report provides comprehensive insights about 20+ companies, including Kartos Therapeutics, AOP Orphan Pharmaceuticals, Biokine Therapeutics, Incyte Corporation, Sana Biotechnology, Novartis, Nerviano Medical Sciences, Sun Pharma Advanced Research Company and others, developing … Continue reading →

Schizophrenia Clinical Trial Pipeline Expands as 55+ Pharma Companies Progress Novel Therapies Toward Market Entry, Finds DelveInsight | Sunovion Pharmaceuticals, AbbVie, Karuna Therapeutics

Schizophrenia – Pipeline Insight, 2026 DelveInsight’s latest report provides comprehensive insights about 55+ companies, such as Sunovion Pharmaceuticals, AbbVie, Karuna Therapeutics, Boehringer Ingelheim, Merck & Co., MapLight Therapeutics, Denovo Biopharma, Cyclerion Therapeutics, and others, developing several pipeline drugs in the … Continue reading →

Autistic Disorder Pipeline Expands with 25+ Companies and 25+ Therapies in Development Across Clinical Stages, Reveals DelveInsight

Autistic Disorder Pipeline Key Autistic Disorder companies include AbbVie, Yamo Pharmaceuticals, Stalicla SA, Vanda Pharmaceuticals, Paxmedica, SciSparc, Scioto Biosciences, Hoffmann-La Roche, ACADIA Pharmaceuticals Inc., Neurotech International, Neuren Pharmaceuticals, MapLight Therapeutics, Jazz Pharmaceuticals, Axial Therapeutics Inc., and several others. DelveInsight’s “Autistic … Continue reading →

Multiple Sclerosis Pipeline Expands with 80+ Drugs and 75+ Companies Advancing Next-Generation Therapies | DelveInsight

Multiple Sclerosis Pipeline Multiple Sclerosis companies include Novartis, Sanofi, Immunic, Biocad, Apimeds, Genentech (Roche), Merck, AB Science, Apurano Pharmaceuticals, Biogen, Tiziana Life Sciences, Worg Pharmaceuticals, Antisense Therapeutics, RemeGen, Atara Biotherapeutics, Contineum Therapeutics, Stem Cell Medicine Ltd., Ever Supreme Bio Technology … Continue reading →

HER2-Negative Metastatic Breast Cancer Market Expected to Transform Significantly Through 2034, According to DelveInsight | Genentech, AstraZeneca, Merck Sharp & Dohme LLC, Gilead Sciences, BeiGene

HER2-Negative Metastatic Breast Cancer Market Major companies actively participating in the HER2-Negative Metastatic Breast Cancer market include Genentech, Inc., AstraZeneca, Merck Sharp & Dohme LLC, Gilead Sciences, BeiGene, Eisai Inc., Novartis Pharmaceuticals, Adagene Inc., Jiangsu HengRui Medicine Co., Ltd., Pfizer, … Continue reading →

Atopic Dermatitis Pipeline Expands with 120+ Therapies and 100+ Companies Advancing Novel Treatments, Reveals DelveInsight Report

Atopic Dermatitis Pipeline Atopic Dermatitis companies including Pfizer, Kymera Therapeutics, BenevolentAI, AstraZeneca, Qurient, Sterna Biologicals, Vanda Pharmaceuticals, and Arcutis Biotherapeutics, among others are actively developing treatment options for atopic dermatitis. The “Atopic Dermatitis Pipeline Insight, 2026” report by DelveInsight presents … Continue reading →

Chronic Spontaneous Urticaria Pipeline Expands with 25+ Therapies and 20+ Companies Advancing Next-Generation Treatments by 2026 | DelveInsight

Chronic Spontaneous Urticaria Pipeline Chronic Spontaneous Urticaria Companies include Novartis, Hangzhou Highlightll Pharmaceutical Co., Ltd, Celldex Therapeutics, Jemincare, Yuhan Corporation, United BioPharma, Septerna, Recludix Pharma, among others. DelveInsight’s report titled “Chronic Spontaneous Urticaria Pipeline Insight 2026” offers an extensive evaluation … Continue reading →

Chronic Obstructive Pulmonary Disease Clinical Trial Pipeline Gains Momentum: 65+ Companies Lead the Charge in Pioneering New Treatments | DelveInsight

DelveInsight’s “Chronic Obstructive Pulmonary Disease Pipeline Insight 2026” report provides comprehensive insights about 65+ companies and 70+ pipeline drugs in the Chronic Obstructive Pulmonary Disease pipeline landscape. It covers the Chronic Obstructive Pulmonary Disease pipeline drug profiles, including clinical and … Continue reading →